Back to News
Market Impact: 0.2
Citigroup Initiates Coverage of Nuvation Bio with Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Citigroup initiated coverage of Nuvation Bio (NYSE: NUVB) with a Buy recommendation on September 30, 2026. Nuvation Bio shares closed at $5.62 on September 29; the positive analyst initiation could support near-term investor sentiment but provides no disclosed price target or fundamental estimate changes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
C0.10
NUVB0.55
More News
- Moderna has been on a tear since mid-August. Citi now sees it plunging 60%
- Why is Moderna stock down 4% today?
- Warner Bros Discovery stock hits 52-week high at $30.93
- Moderna Stock Slumps as Citi Says It's Time to Sell After 500% Rally This Year
- BMW targets 3%-5% auto margin by 2028 after China-linked profit warning
- Why is LyondellBasell stock sliding today?